SCHEDULE: JPMorgan Discloses 4.9% Stake in Karyopharm

JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 4.9% beneficial ownership stake in Karyopharm Therapeutics Inc. as of September 30, 2025.

Summary

• JPMorgan Chase & Co. reported beneficial ownership of 427,624 shares of Karyopharm Therapeutics Inc. common stock.
• This ownership represents 4.9% of the class of securities.
• The filing is an Amendment No. 1 to Schedule 13G, indicating a previous filing for this stake.
• The event date requiring this filing was September 30, 2025.
• JPMorgan Chase & Co. holds sole voting power and sole dispositive power over all 427,624 shares.
• The filing was made by JPMorgan Chase & Co. as a parent holding company, with J.P. Morgan Securities PLC and J.P. Morgan Securities LLC identified as relevant subsidiaries.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual disclosure of beneficial ownership by an institutional investor. It does not contain information that would inherently be considered positive or negative regarding the issuer's performance or prospects.

Positives

• The disclosure of a significant institutional holding by JPMorgan Chase & Co. may signal confidence in Karyopharm Therapeutics Inc. from a major financial entity.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Karyopharm Therapeutics Inc.'s operational or financial performance.

Management Comments

• JPMorgan Chase & Co. certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

Schedule 13G filings are standard disclosures by institutional investors who acquire beneficial ownership of more than 5% of a company's stock, or in this case, an amendment to a previous filing. JPMorgan Chase & Co. is a global financial services firm, and its investment in Karyopharm Therapeutics Inc., a biopharmaceutical company, represents a routine portfolio holding rather than a strategic or activist position, given the nature of a 13G filing and the stated purpose of holding shares in the ordinary course of business.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holding in Karyopharm Therapeutics Inc., which can influence market perception and liquidity.

Key Dates

Keywords

Karyopharm Therapeutics, JPMorgan Chase, Schedule 13G, beneficial ownership, common stock, institutional investor, equity stake